TM-38837 is a small molecule

inverse agonist In pharmacology, an inverse agonist is a drug that binds to the same receptor as an agonist but induces a pharmacological response opposite to that of the agonist. A neutral antagonist has no activity in the absence of an agonist or inverse ago ...

antagonist An antagonist is a character in a story who is presented as the chief foe of the protagonist. Etymology The English word antagonist comes from the Greek ἀνταγωνιστής – ''antagonistēs'', "opponent, competitor, villain, enemy, ri ...

of the CB₁ cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of

obesity Obesity is a medical condition, sometimes considered a disease, in which excess body fat has accumulated to such an extent that it may negatively affect health. People are classified as obese when their body mass index (BMI)—a person's ...

and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials. TM-38837 is among the first of a new generation of

cannabinoid receptor antagonist A cannabinoid receptor antagonist, also known simply as a cannabinoid antagonist or as an anticannabinoid, is a type of cannabinoidergic drug that binds to cannabinoid receptors (CBR) and prevents their activation by endocannabinoids. They includ ...

designed to avoid the

central nervous system The central nervous system (CNS) is the part of the nervous system consisting primarily of the brain and spinal cord. The CNS is so named because the brain integrates the received information and coordinates and influences the activity of all p ...

liabilities of the first generation CB₁ receptor antagonists such as

rimonabant Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in t ...

References

External links

Experimental obesity drug avoids brain effects that troubled predecessors
press release Anorectics CB1 receptor antagonists Peripherally selective drugs Alkyne derivatives Thiophenes Chloroarenes Trifluoromethyl compounds Pyrazoles {{cannabinoid-stub

See also

References

External links